Alzheimer Scotland Welcomes Promising Early Findings From Tarenflurbil Study
May 15th 2008Drug InformationAlzheimer's / Dementia News XML/RSS Feed
Alzheimer Scotland welcomes the recent findings from Professor Gordon Wilcock’s randomised phase II trial of tarenflurbil in patients with mild to moderate Alzheimer’s Disease, but cautions that the phase III stage will be crucial in ascertaining its true potential. The Oxford-based scientists, working with researchers across the world, found that there was a dose-related effect on measures of daily activities and function in patients with mild Alzheimer’s Disease.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
